Clinical Effects of Oral Valiltramiprosate Treatment in APOE4 Carriers with Mild Cognitive Impairment (MCI): Results of the Phase 2 Study Long-term Extension over 3 Years (P6-12.013) | Synapse

⌘+K

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer’s Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial2025 · 22 citations
2Effects of Oral Valiltramiprosate on Clinical Efficacy, Safety, and Brain Volume Outcomes in APOE4/4 Homozygotes with Early Alzheimer’s Disease (AD): Topline Results of the 78-week Phase 3 APOLLOE4 Trial (P1-12.001)Human Clinical Trial · 2026
3Biomarker-positive APOE4 Carriers with MCI Show Cognitive Stability over 4 Years of Oral Valiltramiprosate/ALZ-801 Treatment: MMSE Responder Analysis from the ALZ-801 Phase 2 Long-term Extension Study (P4-13.014)Early-Phase Clinical Trial · 2026
4Correlations between Clinical and Brain Volume Effects of Oral Valiltramiprosate in APOE4/4 Homozygotes with MCI: Pre-specified Analyses of the Phase-3 APOLLOE4 78-Week Trial in APOE4/4 Homozygotes with Early Alzheimer’s Disease (AD) (P6-12.010)Human Clinical Trial · 2026
5Reassessing Amyloid Modulation: Clinical Efficacy and Safety of Valiltramiprosate in Alzheimer’s Disease (P1-12.007)Human Clinical Trial · 2026

More from Neurology